Prostaglandin E
Cancer vaccines
Dendritic cells
Prostaglandin E2
TLR agonists
Tumor-specific CD8+ T cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
02
2019
accepted:
31
12
2019
pubmed:
27
2
2020
medline:
4
6
2020
entrez:
27
2
2020
Statut:
ppublish
Résumé
Mature dendritic cells (DCs) represent cellular adjuvants for optimal antigen presentation in cancer vaccines. Recently, a combination of prostaglandin E
Identifiants
pubmed: 32100075
doi: 10.1007/s00262-019-02470-1
pii: 10.1007/s00262-019-02470-1
pmc: PMC7223547
doi:
Substances chimiques
Toll-Like Receptor 3
0
Dinoprostone
K7Q1JQR04M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029-1042Subventions
Organisme : EU-TRANSCAN
ID : ATRT PepVac
Organisme : Parents Initiative Group for Children with Leukemia and Solid Tumors Würzburg
ID : unrestricted grant
Références
Eur J Immunol. 2013 Oct;43(10):2554-65
pubmed: 23836147
Cancer Immunol Immunother. 2018 Oct;67(10):1545-1558
pubmed: 30054667
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
J Transl Med. 2011 Sep 13;9:151
pubmed: 21910911
Blood. 2011 Nov 17;118(20):5498-505
pubmed: 21972293
Cancer Res. 2008 Sep 15;68(18):7520-9
pubmed: 18794140
J Immunol. 2001 Nov 1;167(9):5027-33
pubmed: 11673511
Cancer Immunol Immunother. 2018 Dec;67(12):1911-1918
pubmed: 29644387
J Clin Invest. 2015 Sep;125(9):3401-12
pubmed: 26214521
J Immunol. 2007 Oct 15;179(8):5033-40
pubmed: 17911588
J Exp Med. 1998 Mar 2;187(5):693-702
pubmed: 9480979
Cell Immunol. 2011;271(2):401-12
pubmed: 21889130
Blood. 2002 Aug 15;100(4):1362-72
pubmed: 12149219
J Transl Med. 2007 Feb 12;5:10
pubmed: 17295916
Cancer Immunol Immunother. 2017 Oct;66(10):1333-1344
pubmed: 28601925
Clin Cancer Res. 2013 Mar 15;19(6):1525-33
pubmed: 23382117
J Transl Med. 2007 Apr 12;5:18
pubmed: 17430585
Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):731-41
pubmed: 15924229
Blood. 2010 Sep 2;116(9):1454-9
pubmed: 20498301
Cancer Immunol Immunother. 2008 Nov;57(11):1589-97
pubmed: 18322684
Cancer Immunol Immunother. 2013 Jul;62(7):1149-59
pubmed: 23657629
J Immunol. 2007 Jun 15;178(12):7794-804
pubmed: 17548617
Nat Immunol. 2005 Aug;6(8):769-76
pubmed: 15995707
J Immunol. 1998 May 1;160(9):4449-56
pubmed: 9574550
Eur J Immunol. 2012 Dec;42(12):3174-9
pubmed: 22949370
Cytotherapy. 2014 Jul;16(7):946-64
pubmed: 24831836
Brain. 2012 Apr;135(Pt 4):1042-54
pubmed: 22418738
J Immunol. 2010 Jan 15;184(2):591-7
pubmed: 20018619
J Exp Med. 2010 Jun 7;207(6):1247-60
pubmed: 20479116
Cancer Immunol Immunother. 2011 Feb;60(2):173-86
pubmed: 20972785
Mol Immunol. 2009 Aug;46(13):2682-93
pubmed: 19545899
Int Immunopharmacol. 2014 Nov;23(1):163-9
pubmed: 25196430
Blood. 2006 Jul 15;108(2):544-50
pubmed: 16537810
Eur J Immunol. 1997 Dec;27(12):3135-42
pubmed: 9464798
Cancer Immunol Immunother. 2010 Aug;59(8):1185-95
pubmed: 20336295
Biochim Biophys Acta. 2015 Apr;1851(4):414-21
pubmed: 25038274
Mol Immunol. 2013 Mar;53(3):274-82
pubmed: 22982753
Clin Cancer Res. 2009 Nov 15;15(22):7036-44
pubmed: 19903780
Blood. 2001 Jun 1;97(11):3466-9
pubmed: 11369638
Blood. 2002 Aug 15;100(4):1354-61
pubmed: 12149218
Nat Protoc. 2014 Apr;9(4):950-66
pubmed: 24675735
J Immunol. 2008 Oct 15;181(8):5296-305
pubmed: 18832685
Front Oncol. 2015 Jun 17;5:98
pubmed: 26137448
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Cancer Res. 2004 Sep 1;64(17):5934-7
pubmed: 15342370
J Immunol. 2004 Mar 1;172(5):2818-26
pubmed: 14978082
Vaccine. 2007 Oct 10;25(41):7145-52
pubmed: 17719152
Mol Immunol. 2013 Jul;54(3-4):284-95
pubmed: 23337716